References
- Munro JF. Clinical aspects of the treatment of obesity by drugs: a review. Int J Obes 1979: 3: 171–80
- Bray GA. The obese patient. Philadelphia WB Saunders. 1976: 359–61
- Craddock D. Obesity and Its management. 3rd ed. New York: Longman (Churchill-Livingstone). 1978: 92–109
- Elliott BJ. A double blind controlled study of the use of diethylpropion hydrochloride (Tenuate) in obese patients in a rural practice NZ Med J 1978: 88: 321–2
- Ranquin R, Brems HM. Metabolic effects and anti-obesity action of fenfluramine in prolonged-acting form. Curr Med Res Opln 1977–8: 5: 341–6
- Howard A, ed. Recent advances in obesity research. 1. London: Cambridge Univ Press. 1975: 354
- Butterfield WJ, Whichelow MJ. Fenfluramine and muscle glucose uptake in man. Lancet 1968: 2: 109
- Hudson KD. The anorectic and hypotensive effect of fenfluramine in obesity. J R Coll Gen Pract 1977: 27: 497–501
- Stunkard A. Rickels K. Hesbacher P. Fenfluramine in the treatment of obesity. Lancet 1973: 1: 503–5
- Evans ER, Wallace MG. A multi-centre trial of mazindol (‘Teronac’) in general practice in Ireland. Curr Med Res Opin 1975: 3: 132–7
- LeRiche H. A study of appetite suppressants in a general practice. Can Med Assoc J 1960: 82: 467–70
- Steel JM, Munro JF, Duncan LJ. A comparative trial of different regimens of fenfluramine and phentermine in obesity. Practitioner 1973: 211: 232–6
- Griboff SI. Berman R. A double blind clinical evaluation of a phenylpropanolamine-caffeine-vita-mine combination and a placebo in the treatment of exogenous obesity Curr Ther Res 1975: 17: 535–44
- Dietz WH. Amphetamine like reactions to phenylpropanolamine. JAMA 1981: 245: 601–2
- Horowitz JD. Lang WJ. Howes LG. et al. Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations. Lancet 1980: 1: 60–1
- Simeons AT. Chorionic gonadotropin in the obese. Lancet 1962: 1: 47–8
- Stein MR, Julis RE. Peck CC. et al. Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study. Am J Clin Nutr 1976: 29: 940–8
- Shetty KR, Kalkhoff RK. Human chorionic gonadotropin (HCG) treatment of obesity. Arch Intern Med 1977: 137: 151–5
- Van Itallie TB. Hirsch J. The treatment of obesity. (Letter) Am J Clin Nutr 1973: 26: 1039–41
- Young RL. Fuchs RJ. Woltjen MJ. Chorionic gonadotropin in weight control: a double blind crossover study. JAMA 1976: 236: 2495–7
- Rivlin RS. The use of hormones in the treatment of obesity. Curr Concepts Nutr 1975: 3: 151–62
- Bray GA, Melvin KE, Chopra LJ. Effects of triiodothyronine on some metabolic responses of obese patients. Am J Clin Nutr 1973: 26: 715–21
- Bray GA. Raben MS, Londono J, et al. Effects of triiodothyronine, growth hormone and anabolic steroids on nitrogen excretion and oxygen consumption of obese patients. J Clin Endocrinol Metab 1971: 33: 293–300
- Collipp PJ. The treatment of exogenous obesity by medicated benzocalne candy: a double blind placebo study. Obes Bariatr Med 1981: 10(5): 123–7
- Gould WL. Obesity and hypertension: the importance of a safe compound to control appetite. NC Med J 1950: 11: 327–32
- McClure CW, Brusch CA. Treatment of oral syndrome obesity with non-traditional appetite control plan J Am Med Worn Assoc 1973: 28: 239–48
- Anorectics have limited use in treatment of obesity. FDA Drug Bull 1972 Dec
- Stunkard AJ, Craighead LW, O'Brien R. Con trolled trial of behavior therapy, pharmacology and their combination in the treatment of obesity. Lancet 1980: 2: 1045–7